Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 5:17:605-627.
doi: 10.2147/OTT.S457749. eCollection 2024.

Nrf2-Mediated Antioxidant Response and Drug Efflux Transporters Upregulation as Possible Mechanisms of Resistance in Photodynamic Therapy of Cancers

Olawale Razaq Ajuwon  1 , Fleury Augustine Nsole-Biteghe  2 , Jean Delacroix Ndong  3 , Lester Merlin Davids  4 , Basiru Olaitan Ajiboye  1 , Bartholomew Brai  1 , Fisayo Abraham Bamisaye  1 , John Adeolu Falode  1 , Ikenna Maximillian Odoh  1   5 , Kabirat Iyabode Adegbite  6 , Bosede Oluwasayo Adegoke  7 , Monde Ntwasa  8 , Sogolo Lucky Lebelo  8 , Ademola Olabode Ayeleso  8   9
Affiliations
Review

Nrf2-Mediated Antioxidant Response and Drug Efflux Transporters Upregulation as Possible Mechanisms of Resistance in Photodynamic Therapy of Cancers

Olawale Razaq Ajuwon et al. Onco Targets Ther. .

Abstract

Photodynamic therapy (PDT) is a groundbreaking approach involving the induction of cytotoxic reactive oxygen species (ROS) within tumors through visible light activation of photosensitizers (PS) in the presence of molecular oxygen. This innovative therapy has demonstrated success in treating various cancers. While PDT proves highly effective in most solid tumors, there are indications that certain cancers exhibit resistance, and some initially responsive cancers may develop intrinsic or acquired resistance to PDT. The molecular mechanisms underlying this resistance are not fully understood. Recent evidence suggests that, akin to other traditional cancer treatments, the activation of survival pathways, such as the KEAP1/Nrf2 signaling pathway, is emerging as an important mechanism of post-PDT resistance in many cancers. This article explores the dual role of Nrf2, highlighting evidence linking aberrant Nrf2 expression to treatment resistance across a range of cancers. Additionally, it delves into the specific role of Nrf2 in the context of photodynamic therapy for cancers, emphasizing evidence that suggests Nrf2-mediated upregulation of antioxidant responses and induction of drug efflux transporters are potential mechanisms of resistance to PDT in diverse cancer types. Therefore, understanding the specific role(s) of Nrf2 in PDT resistance may pave the way for the development of more effective cancer treatments using PDT.

Keywords: Nrf2; antioxidant response; oxidative stress; photodynamic therapy; tumor resistance.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Photochemical generation of ROS during PDT. Upon absorption of light of appropriate wavelength by the PS, an electron is elevated to an excited singlet state (S1) from the singlet ground state (S0). This excited singlet state is transient and can release energy through photon emission (fluorescence). Alternatively, it may undergo intersystem crossing, leading to the formation of a long-lived excited triplet state (T1). The T1 state is responsible for generating reactive species, including O2•-, H2O2, HO• and 1O2 through both type I and type II reactions.
Figure 2
Figure 2
Protein structure of (A) Nrf2 and (B) KEAP1 showing different domains.
Figure 3
Figure 3
Activation and response of Nrf2. Under normal condition, KEAP1 binds Nrf2 and package it for ubiquitination and proteosomal degradation with the help of Cullin 3-E3 ubiquitin ligase. In the presence of a stressor such as ROS and electrophiles, Nrf2 is activated and translocated into the nucleus where its binding to the antioxidant response element sequence leads to transcription of different cytoprotective genes.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217–222. doi:10.2991/jegh.k.191008.001 - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. World Health Organization. Global health estimates 2016: disease burden by cause, age, sex, by country and by region, 2000–2016. World Health Organization. 2018; Geneva. Available from: https://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.... Accessed August 30, 2021.
    1. Kalubula M, Shen H, Makasa M, Liu L. Epidemiology of cancers in Zambia: a significant variation in cancer incidence and prevalence across the nation. Malawi Med J. 2021;33(3):186–195. doi:10.4314/mmj.v33i3.6 - DOI - PMC - PubMed
    1. Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a Phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: radiation therapy oncology group trial 9514. Cancer. 2010;116(19):4613–4621. doi:10.1002/cncr.25350 - DOI - PMC - PubMed

Grants and funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Article Processing Charge for publication was paid by University of South Africa, Pretoria, South Africa.

LinkOut - more resources